Skip to main content
SpringerLink
Log in

Phase II study of 2′-deoxycoformycin in patients with renal cell carcinoma

A National Cancer Institute of Canada Clinical Trials Group study

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The National Cancer Institute of Canada Clinical Trials Group undertook a phase II study of 2′-deoxycoformycin in patients with metastatic renal cell carcinoma. When 2′-deoxycoformycin 4 mg/m2 was administered intravenously weekly for three weeks then every two weeks no significant antitumor activity was noted in 19 evaluable patients. Toxic effects experienced were as expected, consisting primarily of nausea/vomiting, anorexia, and lethargy. It is concluded that 2′-deoxycoformycin at this dose and schedule has no clinical activity in the treatment of metastatic renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Poplack DG, Sallan SE, Rivera G, Hollenberg J, Murphy SB, Blatt J, Lipton JM, Venner P, Glaubiger DL, Ungerleider R, Johns D: Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res 41:3343–3346, 1981

    Google Scholar 

  2. Spiers ASD, Moore D, Cassileth PA, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ: Remis 1. sions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 316:825–830, 1987

    Google Scholar 

  3. Johnston JB, Eisenhauer E, Corbett WEN, Scott JG, Zaentz SD: Efficacy of 2′-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 80:765–769, 1988

    Google Scholar 

  4. Kraut EH, Bouroncle BA, Grever MR: Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 7:168–172, 1989

    Google Scholar 

  5. Grever MR, Siaw MFE, Jacob WF, Neidhart JA, Miser JS, Coleman MS, Hutton JJ, Balcerzak SP: The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57:406–417, 1980

    Google Scholar 

  6. Prentice HG, Russel NH, Lee N, Blacklock H, Smyth JF, Russell NH, Ganeshaguru K, Piga A, Hoffbrand AV: Therapeutic selectivity of and prediction of response to 2′-deoxycoformycin in acute leukemia. Lancet 2:1250–1254, 1981

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cross Cancer Institute, Edmonton, Alberta

    Peter Venner

  2. NCIC Clinical Trials Group, Kingston, Ontario, Canada

    Elizabeth A. Eisenhauer

  3. Nova Scotia Cancer Treatment and Research Foundation, Halifax, Nova Scotia

    Rafal Wierzbicki

  4. Manitoba Cancer Treatment Research Foundation, Winnipeg, Manitoba, Canada

    James Johnston

Authors
  1. Peter Venner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth A. Eisenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rafal Wierzbicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Venner, P., Eisenhauer, E.A., Wierzbicki, R. et al. Phase II study of 2′-deoxycoformycin in patients with renal cell carcinoma. Invest New Drugs 9, 273–275 (1991). https://doi.org/10.1007/BF00176983

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00176983

Key words

Search

Navigation